News & Perspective

Public health groups are lining up to oppose 'piecemeal' efforts to fund federal agencies.

Clinical trials will test a candidate vaccine for H7N9 flu in varying doses, some with immune boosters.

A new molecular strategy could diffuse some of the controversy over lab-modified flu viruses.

Will future research include lab-modified strains that are more transmissible and require tighter safety measures?

Experts say some properties of H7 viruses may lend themselves to human adaptation.